On 09 November 2020, Pfizer Inc. (NYSE:PFE) and BioNTech SE (Nasdaq:BNTX) together announced that their mRNA-based vaccine candidate, BNT162b2 was found 90% effective in preventing COVID-19 in participants without evidence of previous SARS-CoV-2 infection in the first interim efficacy analysis.
In the process, 94 confirmed COVID-19 patients were analysed. The study enrolled 43,538 participants. 42% of these participants had diverse backgrounds. Further, no safety concerns were seen.
Clinical trial would continue through to final analysis at 164 confirmed cases to gather more data and characterize the performance of vaccine against other study endpoints.